Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248421 | 0.90 | CCNA2 (0.49) | MAPTMEN1KMT2ALMNAPSMD14 | |
| SCHEMBL1250879 | 0.81 | CDK5 (0.54) | MAPTMEN1KMT2ACDK5CDK5R1 | |
| SCHEMBL5725681 | 0.75 | CDK5 (0.48) | MAPTMEN1KMT2ALMNACDK5 | |
| SCHEMBL1250354 | 0.75 | CCNA2 (0.49) | MAPTMEN1KMT2ACDK5CDK5R1 | |
| SCHEMBL7757019 | 0.75 | MAPT (0.48) | MAPTMEN1KMT2ALMNAPSMD14 | |
| SCHEMBL1248186 | 0.74 | MAPT (0.45) | MAPTMEN1KMT2ALMNAPSMD14 | |
| SCHEMBL1287130 | 0.74 | BCL2 (0.48) | MAPTMEN1KMT2AJUNNFKB1 | |
| SCHEMBL1249747 | 0.73 | MAPT (0.46) | MAPTMEN1KMT2ALMNAPSMD14 | |
| SCHEMBL7758207 | 0.73 | MEN1 (0.57) | MAPTMEN1KMT2ALMNACDK5 | |
| SCHEMBL1248135 | 0.72 | MAPT (0.45) | MAPTMEN1KMT2ALMNAPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | MAPT 13/4885MEN1 3396/4885KMT2A 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.